Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)’s share price traded down 3.5% during trading on Tuesday . The stock traded as low as $36.32 and last traded at $36.33, with a volume of 129,091 shares trading hands. The stock had previously closed at $37.66.

Several equities research analysts have recently issued reports on PCRX shares. Zacks Investment Research upgraded shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, April 26th. Mizuho restated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, May 26th. TheStreet downgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, May 2nd. Wedbush restated an “outperform” rating and issued a $113.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, April 20th. Finally, Brean Capital downgraded shares of Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, July 1st. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the stock. Pacira Pharmaceuticals presently has an average rating of “Buy” and an average price target of $74.54.

The company’s market capitalization is $1.36 billion. The stock’s 50-day moving average price is $38.81 and its 200 day moving average price is $51.09.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings results on Monday, May 2nd. The company reported $0.15 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.07 by $0.08. The company earned $65.50 million during the quarter, compared to analysts’ expectations of $67.11 million. During the same quarter last year, the firm posted $0.27 earnings per share. Pacira Pharmaceuticals’s revenue for the quarter was up 12.3% compared to the same quarter last year. Equities analysts anticipate that Pacira Pharmaceuticals Inc. will post $0.33 EPS for the current year.

In other news, Director Mark A. Kronenfeld sold 900 shares of Pacira Pharmaceuticals stock in a transaction on Monday, June 6th. The stock was sold at an average price of $46.95, for a total value of $42,255.00. Following the completion of the transaction, the director now directly owns 2,950 shares in the company, valued at $138,502.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Kristen Marie Williams sold 600 shares of Pacira Pharmaceuticals stock in a transaction on Monday, June 6th. The shares were sold at an average price of $47.20, for a total value of $28,320.00. Following the completion of the transaction, the chief accounting officer now owns 6,900 shares of the company’s stock, valued at $325,680. The disclosure for this sale can be found here.

Several institutional investors recently made changes to their positions in the stock. KBC Group NV boosted its position in shares of Pacira Pharmaceuticals by 2,685.7% in the fourth quarter. KBC Group NV now owns 28,024 shares of the company’s stock valued at $2,152,000 after buying an additional 27,018 shares during the period. Stephens Investment Management Group LLC boosted its position in shares of Pacira Pharmaceuticals by 10.0% in the fourth quarter. Stephens Investment Management Group LLC now owns 540,687 shares of the company’s stock valued at $41,519,000 after buying an additional 49,018 shares during the period. Stephens Inc. AR boosted its position in shares of Pacira Pharmaceuticals by 3.9% in the fourth quarter. Stephens Inc. AR now owns 21,557 shares of the company’s stock valued at $1,655,000 after buying an additional 806 shares during the period. Morgan Stanley boosted its position in shares of Pacira Pharmaceuticals by 28.7% in the fourth quarter. Morgan Stanley now owns 120,614 shares of the company’s stock valued at $9,261,000 after buying an additional 26,865 shares during the period. Finally, Mutual of America Capital Management LLC boosted its position in shares of Pacira Pharmaceuticals by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 24,198 shares of the company’s stock valued at $1,858,000 after buying an additional 142 shares during the period.

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.